Immunotherapeutic strategies for bladder cancer.

Détails

Ressource 1Télécharger: BIB_A25269F0E43E.P001.pdf (738.28 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_A25269F0E43E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immunotherapeutic strategies for bladder cancer.
Périodique
Human Vaccines and Immunotherapeutics
Auteur⸱e⸱s
Chevalier M.F., Nardelli-Haefliger D., Domingos-Pereira S., Jichlinski P., Derré L.
ISSN
2164-554X (Electronic)
ISSN-L
2164-5515
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
10
Numéro
4
Pages
977-981
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Bladder cancer is a common urologic malignancy with rising incidence in the elderly population. In most cases, bladder cancer is non-muscle-invasive at diagnosis and shows dramatically high recurrence rates, although current treatments often reduce the risk of disease progression. Immunotherapy using intravesical instillation of Bacillus Calmette-Guérin (BCG) remains the most effective therapy for patients with high risk tumors. However, BCG-therapy has important limitations including substantial adverse events and frequent treatment failure. Thus, it appears crucial to either improve or replace current therapy using new immunotherapeutic strategies. Here, we discuss the clinical trials that assessed therapeutic vaccination of bladder cancer patients using tumor associated antigens and we also argue for novel approaches arising from murine models. Vaccination routes to induce appropriate T-cell homing in the tumor site as well as the use of local immunostimulation to enhance recruitment of vaccine-induced T cells are discussed to highlight what we believe is a promising therapeutic vaccination strategy for patients with non-muscle-invasive bladder cancer.
Mots-clé
Aged, Cancer Vaccines/administration & dosage, Cancer Vaccines/immunology, Clinical Trials as Topic, Humans, Immunotherapy/methods, T-Lymphocytes/immunology, Treatment Outcome, Urinary Bladder Neoplasms/therapy
Pubmed
Web of science
Création de la notice
28/06/2014 16:19
Dernière modification de la notice
20/08/2019 16:08
Données d'usage